CRLBFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Cresco Labs Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 6, 2026
$0.58−0.02 (-3.13%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Cresco Labs Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Retail | $433.08M | $471.75M | – | 66.0% | -8.2% |
| Wholesale | $222.77M | $252.59M | – | 34.0% | -11.8% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Wholesale | – | $252.59M | $306.36M | – | – |
| Retail | – | $471.75M | $464.52M | – | – |
By region
From the segment and revenue-disaggregation notes of Cresco Labs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.